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ABSTRACT
MicroRNAs are noncoding regulators of gene expression, which act by repressing protein translation and/or degrading mRNA.
Many have been shown to drive tumorigenesis in cancer, but functional studies to understand their mode of action are
typically limited to single-target genes. In this study, we use synthetic biotinylated miRNA to pull down endogenous targets of
miR-182-5p. We identified more than 1000 genes as potential targets of miR-182-5p, most of which have a known function in
pathways underlying tumor biology. Specifically, functional enrichment analysis identified components of both the DNA
damage response pathway and cell cycle to be highly represented in this target cohort. Experimental validation confirmed that
miR-182-5p-mediated disruption of the homologous recombination (HR) pathway is a consequence of its ability to target
multiple components in that pathway. Although there is a strong enrichment for the cell cycle ontology, we do not see
primary proliferative defects as a consequence of miR-182-5p overexpression. We highlight targets that could be responsible
for miR-182-5p-mediated disruption of other biological processes attributed in the literature so far. Finally, we show that miR-
182-5p is highly expressed in a panel of human breast cancer samples, highlighting its role as a potential oncomir in breast cancer.
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INTRODUCTION
MicroRNAs (miRNAs) are short (∼22 nt), single-stranded,
noncoding, negative regulators of gene expression in eukary-
otes. An individual miRNA is capable of targeting hundreds
of distinct mRNAs (Thomas et al. 2010), and together the
1150+ human miRNAs are believed to modulate more than
a third of the mRNA species encoded in the genome (Bartel
2009). miRNAs have been shown to be biologically significant
in various cellular processes such as cell differentiation, pro-
liferation, apoptosis, and development in humans as well as
other model organisms (for review, see Kloosterman and
Plasterk 2006). Thus, deregulation of miRNAs can result in
abnormal growth and development leading to several disor-
ders, including cancer.
Since the first study showing direct evidence of miR-17-92
acting as an oncogene in B-cell lymphomas (He et al. 2005),
the role of miRNAs as oncogenes or tumor suppressors has
been reported in almost every type of cancer. In the case of
breast cancer, miRNA expression profiling of more than 70
primary tumors and cell lines identified five miRNAs
(miR-10b, miR125b, miR-145, miR-21, and miR-155) that
were consistently deregulated (Iorio et al. 2005). miR-10b
has subsequently been shown to play a role in the metastatic
ability of breast cancer, positively regulating cell migration
and invasion (Ma et al. 2007). miR-21, initially shown to
be overexpressed in several human breast cancers (Iorio
et al. 2005; Volinia et al. 2006), was later established to func-
tion as an oncogene (Si et al. 2007) by targeting anti-meta-
static genes TPM1 (Zhu et al. 2007), PDCD4 (Frankel et al.
2008), and Maspin (Zhu et al. 2008). These and other studies
highlighted the importance of identifying miRNAs driving
tumorigenesis and of accurate prediction followed by charac-
terization of their biologically relevant targets. Intriguingly,
some miRNAs (such as miR-17-5p) have been shown to
have a dual role as both oncogenes and tumor suppressors,
depending on the cellular model under investigation (He
et al. 2005; Hossain et al. 2006; Volinia et al. 2006; Zhang
et al. 2006), and this has been due to a combination of the
gene networks targeted by the miRNA and the expression
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levels of target transcripts (Cloonan et al. 2008). These dual-
functioning miRNAs are of particular importance because
they are key biological hubs that could be used to leverage a
therapeutic outcome.
Another miRNA with this potential dual function is miR-
182-5p. This miRNA was first identified and cloned from the
mouse eye (Lagos-Quintana et al. 2003) and has shown to be
tumorigenic in melanoma (Segura et al. 2009) and endome-
trial cancer (Myatt et al. 2010) and is overexpressed in lung
(Cho et al. 2009), prostate (Schaefer et al. 2010), and colon
cancers (Sarver et al. 2009). It is also up-regulated in primary
gliomas and is associated with poor prognosis for patients
with metastasis (Jiang et al. 2010). In contrast, a tumor-sup-
pressive role for miR-182-5p has been established in lung
cancer (Sun et al. 2010; Zhang et al. 2011), and gastric adeno-
carcinoma (Kong et al. 2012), where overexpression of this
miRNA leads to suppression of cell growth. Despite the wide-
spread association of altered miR-182-5p expression across a
range of human cancers, only a few targets have been identi-
fied so far; including FOXO3, MITF (Segura et al. 2009),
FOXO1 (Guttilla and White 2009), BRCA1 (Moskwa et al.
2011), CTTN (Sun et al. 2010), RGS17 (Sun et al. 2010),
and more recently CREB1 (Kong et al. 2012) and MTSS1
(Liu et al. 2012). Recently, miR-182-5p, along with other
miRNAs in its cluster, has been shown to affect apoptosis,
senescence, proliferation, and migration/motility in medul-
loblastoma (Weeraratne et al. 2012). We believe that a
more thorough and systematic screen of miR-182-5p targets
will help elucidate its biological role in tumor biology.
Accurate miRNA target gene prediction has been challeng-
ing due to several reasons, mostly the constantly evolving hy-
potheses surrounding the miRNA–mRNA target recognition
principles. Initial studies showed miRNAs binding to the 3′
UTRs of their target mRNAs by partial complementation
spanning 6–8 nt of the seed sequence in their 5′ end (Lim
et al. 2005), and most computational target-prediction pro-
grams rely on evolutionary conservation of these seed sites
to limit the high false-positive rates for such small sequence
motifs (Brennecke et al. 2005; Krek et al. 2005; Lewis et al.
2005). Even with this limitation, there are typically hundreds
to thousands of targets predicted for a single miRNA, and
many are shown to be false positives when interrogated by lu-
ciferase assays (Bentwich 2005; Rajewsky 2006; Baek et al.
2008; Cloonan et al. 2008). Along with the lack of overlap
between targets predicted by different programs (Saito
and Saetrom 2010), this limits streamlined analysis of biolog-
ically relevant targets and their subsequent experimental
validation.
Our study overcomes these obstacles by using a combina-
tion of biotinylated synthetic miRNA pull-downs (Cloonan
et al. 2011) to capture endogenous mRNA targets of miR-
182-5p, and microarray expression profiling to identify
them. We show that miR-182-5p targets more than 1000
genes including many well-characterized oncogenes and tu-
mor suppressors. Its targets include multiple components of
the BRCA1-dependent DNA damage response pathway and
the downstream G2 cell cycle checkpoint. In the context of
breast cancer, we demonstrate that miR-182-5p’s primary
effect is to mediate the double-stranded DNA damage re-
sponse. Finally, we observe overexpression of miR-182-5p
in a panel of human breast cancer patient samples, estab-
lishing its role as a potential oncomir in human breast
cancer.
RESULTS
Identification of putative miR-182-5p targets using
biotinylated pull-down method
Endogenous targets of miR-182-5p in HEK293T cells were
captured using biotinylated synthetic miRNAs as described
in Cloonan et al. (2011). Transient transfections of biotiny-
lated miR-182-5p molecules and mock transfections, to be
used as negative controls in the subsequent analysis, were car-
ried out simultaneously in the same cell line. Expression pro-
filing was then performed on the pull-down fraction versus
the mock-transfected samples using microarrays (Fig. 1A).
The false discovery rate (FDR) was calculated to account
for multiple testing (Benjamini and Hochberg 1995).
Probes that met the 5% FDR threshold (for one-sided tests)
and with a fold-change >1.25 were considered significantly
enriched in the pull-down (Fig. 1B). This differential expres-
sion analysis (see Materials and Methods) revealed 1235
probes (1091 genes) to be significantly enriched in the pull-
down fractions (Supplemental Table 1).
Previously validated mRNA targets of miR-182-5p,
BRCA1, RGS17, and FOXO3 were significantly enriched in
our pull-down (P-values ∼0.005) (Fig. 1B), confirming the
validity of our approach. Although there is no large-scale ex-
perimental validation of miR-182-5p targets with which to
compare, we would expect to see an enrichment of predicted
targets in our biotin pull-down data. To assess this, we com-
pared the TargetScan (Lewis et al. 2005) predicted targets of
miR-182-5p with our significantly enriched genes from the
biotin pull-down (Fig. 1B,C). We observed an overlap of
113 genes, which was significantly more than we would pre-
dict by chance (χ2 test; P≈ 8 × 10−24; degrees of freedom =
1), indicating that the biotin pull-down is enriched for
predicted targets of miR-182-5p. Finally, we selected four
previously uncharacterized targets (CDKN1B, CHEK2,
SMARCD3, and NFKBIB), which also fall within our strin-
gent significance threshold, and asked whether miR-182-5p
could interact with these mRNAs. We cloned the predicted
binding sites into the 3′ UTR of a luciferase reporter gene,
and cotransfected either miR-182-5p mimic or a negative
mimic control, and measured the luciferase activity 48 h
post-transfection. Using this assay, we validated all four bind-
ing sites tested (Fig. 1B,D). Taken together, these results con-
firm that our pull-downs are enriching for genuine targets of
miR-182-5p.
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miR-182-5p targets genes involved
in the DNA damage response
pathway
To infer the broad biological process-
es regulated by miR-182-5p, we per-
formed gene set enrichment analysis
(GSEA) on the full set of experimentally
determined targets miR-182-5p (biotin
pull-down) using Ingenuity Pathway
Analysis (IPA, Ingenuity Systems). The
enrichment of ontologies found in this
set was compared with 10 randomly
generated gene lists of equivalent size.
Supplemental Table 2 lists all “Molec-
ular and Cellular Functions” (P-value
< 0.002), and Supplemental Table 3
lists all “Canonical Pathways” (P-value
< 0.02) associated with the miR-182-
5p-predicted targets where the −log(P-
value) of the enrichment was at least
one standard deviation away from the
mean −log(P-value) from random gene
lists. For all subsequent analysis and
validations, we considered an ontology
as significantly enriched if its −log(P-
value) was at least four standard devia-
tions away from the mean of the −log
(P-value) from the random gene sets
(Cloonan et al. 2008).
Only two molecular processes were
identified above our stringent thresh-
old: “Gene Expression” (160 genes; P-
value≈ 1.15 × 10−11), and “Cell Cycle”
(114 genes; P-value≈ 1.46 × 10−10).
Like many miRNAs, transcription fac-
tors are over-represented in miR-182-
5p targets (Cui et al. 2006). The cell
cycle ontology is similarly broad, en-
compassing a variety of proliferative
and regulatory functions from the direct
control of proliferation to checkpoint
control. Like others (Moskwa et al.
2011), we could not identify a prolifera-
tive defect in MDA-MB-231 cells upon
inducing overexpression of miR-182-
5p (Fig. 2A,B). We constructed three
independent cell lines that could over-
express miR-182-5p in response to
doxycycline (Fig. 2A). Using all three
stable cell lines, we examined the rate
of proliferation (Fig. 2B) and the dis-
tribution of cells in each phase of the
cell cycle (Fig. 2C), but were unable to
detect any substantial differences. We
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FIGURE 1. Identifying targets of miR-182-5p via biotin pull-down. (A) Hierarchical clustering
of microarray data was performed using the plotSampleRelations function in the lumi package.
Total vertical distance between samples indicates similarity. (B) A “volcano plot” showing the
log2-transformed fold-change (mock/pull-down) versus the log10-transformed P-value for that
fold-change for every gene detected above background in the microarray. (Blue) Genes that are
targets validated by previous studies; (orange) genes predicted by TargetScan to be targets of
miR-182-5p; (green) genes selected for validation using luciferase assays (D). There is an apparent
enrichment of the targets in the pull-downs compared with the controls. (C) Venn diagram
showing the overlap of genes between TargetScan-predicted targets of miR-182-5p (also ex-
pressed above background in HEK293Ts) and biotinylated miR-182-5p pull-down-predicted tar-
gets. This overlap is significantly more than expected by chance. (D) Dual luciferase assay used to
validate CHEK2, SMARCD3, CDKN1B, and NFKBIB as targets of miR-182-5p. HEK293T cells
were transiently cotransfected with 20 nM miR-182-5p or control mimic with a pmirGlo-lucif-
erase construct containing the predicted binding site from the indicated target gene. Luciferase
activity was normalized to Renilla activity; (∗) P < 0.05 in a Student’s t-test. The data plotted
are the mean and SEM of three independent biological replicates.
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were also unable to find a significant change in the proportion
of cells in each phase of the cell cycle upon miR-182-5p over-
expression in this system (Fig. 2C), and only a small (5%) ac-
cumulation in the G1 phase of transiently transfected HeLa
cells (Fig. 2D,E). Taken together, we conclude that miR-
182-5p is not sufficient to modulate proliferation or cell cycle
progression in the cell lines tested here.
However, this does not exclude a role
for this miRNA in proliferation in other
biological contexts or other aspects of
cell cycle biology, such as checkpoint
regulation.
We next sought to identify the canon-
ical pathways enriched with predicted
miR-182-5p targets. The most signifi-
cantly enriched pathways were all facets
of the DNA damage response (DDR)
(Supplemental Table 3): “Cell Cycle:
G2/M DNA Damage Checkpoint Regu-
lation” (P-value≈ 2.90 × 10−05), “Role
of BRCA1 in DNA Damage Response”
(P-value ≈ 8.50 × 10−05), “Hereditary
Breast Cancer Signaling” (P-value≈
1.1 × 10−04), “Cyclins and Cell Cycle
Regulation” (P-value≈ 1.49 × 10−04),
“Role of CHK Proteins in Cell Cycle
Checkpoint Control” (P-value≈ 5.6 ×
10−04), and “ATM Signaling” (P-val-
ue ≈ 8.20 × 10−04). To confirm that
this enrichment is not occurring in
response to a foreignmolecule being in-
troduced into these cells, we transiently
transfected 20 nM miR-182-5p mimic
(∼3× the concentration of the biotiny-
lated molecule) into MDA-MB-231
cells and evaluated expression levels of
known DNA repair genes. Figure 3A
shows that only ATF1 changed signifi-
cantly between cells transfected with
miR-182-5p or negative mimic control,
but only to a small extent (1.16×). This
confirms that there is no substantial
and widespread DNA-damage response
as a result of introducing an exogenous
molecule into these cells. To further
verify if this response is miR-182-5p
specific, we performed functional en-
richment analysis on biotin pull-down
targets of othermiRNAs (data generated
in-house). Figure 3B shows the canon-
ical pathway “Role of BRCA1 in DNA
Damage Response” to be highly signifi-
cant only in the miR-182-5p pull-down
analysis. As shown in the figure, the lev-
el of enrichment in the miR-182-5p
pull-down is at least four standard deviations away from
the mean of −log(significance) of other miRNA pull-downs,
suggesting that this enrichment is not occurring by chance
and is a specific response to miR-182-5p overexpression.
DDR is a key pathway in cancer, and its disruption leads to
genetic instability and promotes tumorigenesis (Deng 2006).
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FIGURE 2. Overexpression of miR-182-5p does not induce a proliferative defect. (A) Expression
of miR-182-5p as assessed by qRT-PCR in MDA-MB-231 cells (with low endogenous expression
of miR-182-5p) stably transfected with miR-182-5p whose expression is induced in response to
doxycycline. Shown here are three independent cell lines grown in the presence of 0 or 1000 ng/
mL of doxycycline for 48 h. RNU6B was used as an endogenous control for normalization of ex-
pression. (B) MTT cell proliferation assays of MDA-MB-231 cells stably expressing miR-182-5p.
The graph plots the mean and SEM of the previously studied stable cell lines grown with either 0
or 1000 ng/mL doxycycline. The induction of miR-182-5p does not affect the proliferation rates
of MDA-MB-231 cells. (C) DNA profile analysis of MDA-MB-231 cells stably expressing miR-
182-5p. The graph shows the mean and SEM of the percentage of cells in different cell cycle phas-
es, as assessed by FACS. There was no significant difference between MDA-MB-231 cells express-
ing or not expressing miR-182-5p. (D) Expression of miR-182-5p in HeLa cells transiently
transfected with miR-182-5p mimic or negative mimic control as assessed by qRT-PCR.
RNU6B was used as an endogenous control for normalization of expression. (E) A graph showing
the DNA profile analysis of HeLa cells transiently transfected with either miR-182-5p mimic or a
control mimic. Shown is the mean and SEM of three independent biological replicates, each per-
formed in technical triplicates. (∗) P < 0.05 in a Student’s t-test (n = 3).
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Typically, this pathway is activated in response to double-
stranded breaks (DSBs) leading to cell cycle arrest at either
the p53-dependent G1/S-phase checkpoint or the p53-inde-
pendent G2/M-phase DNA damage checkpoint (Moynahan
et al. 1999;Moynahan and Jasin 2010), and regulates a specific
set of gene products involved in DNA repair, such as BRCA1
(Khanna and Jackson 2001). Disruption to this pathway has
been associated with a wide variety of malignancies including
breast, ovarian, and pancreatic cancer (Lord and Ashworth
2012). Figure 4 shows an overview of this pathway and its
downstream effects, with the pull-down-identified targets of
miR-182-5p highlighted in dark gray. Of the 54 genes in
this pathway, we have now identified 36 (66.66%) as likely tar-
gets of miR-182-5p (Fig. 4; Supplemental Table 4).
A majority (32 of 36) of the miR-182-5p targets in this
pathway are proteins that play a major role in the positive reg-
ulation of the response to DNA damage, so their repression
by miR-182-5p could lead to a disruption of the DDR path-
way. There are, however, two classes of proteins that are an
exception to this coherent model. First is the Cyclin-depen-
dent Kinase 6 (CDK6), which, along with CDK4, is known
to phosphorylate and inactivate RB (RB1), leading to the
cell cycle progression (Meyerson and Harlow 1994). How-
ever, in response to DNA damage, this would typically lead
to an accumulation of genomic instability and is therefore
repressed by p53 (TP53), through p21 (CDKN1A) in vitro
(see Fig. 4; Meyerson and Harlow 1994; Harper et al.
1995). Hence, repression of the CDKs by miR-182-5p would
lead to activation of RB and a cell cycle arrest, enabling effi-
cient DNA repair. The second class is the components of the
SCF complex that are responsible for the ubiquitylation of
several proteins that are essential for the DDR, e.g., SKP1
and 2, components of the SCF complex, which are known
to degrade p27KIP1 (CDKN1B), an essential mediator of cell
cycle arrest in response to DNA damage (Cuadrado et al.
2009). Another component of the SCF complex, BTRC, is
also known to ubiquitylate ATF4, which plays a role in main-
taining genomic integrity (Lassot et al. 2001). The repres-
sion of these two classes of proteins by miR-182-5p could
lead to a normal functioning DDR, which may explain the
tumor-suppressive effects of this miRNA observed in lung
cancer (Sun et al. 2010; Zhang et al. 2011), and human gastric
adenocarcinoma (Kong et al. 2012), in a manner analogous
to miR-17-5p’s dual functionality (He et al. 2005; Hossain
et al. 2006; Volinia et al. 2006; Zhang et al. 2006).
miR-182-5p modulates PARP inhibitor sensitivity
by targeting multiple components of the DNA repair
pathway
miR-182-5p has recently been reported to target BRCA1
(Moskwa et al. 2011), a critical component of the homolo-
gous recombination (HR) pathway, in breast cancer cell lines.
Since it has been shown that some miRNAs concurrently tar-
get functionally related genes to drive a specific biological sig-
nal (Cloonan et al. 2008; Tsang et al. 2010; Ulitsky et al. 2010;
Su et al. 2011) and miR-182-5p targets are enriched for genes
involved in DNA damage repair, we hypothesized that miR-
182-5p’s action on the HR pathway extends beyond the tar-
geting of BRCA1. miR-182-5p targeting of CHEK2, an up-
stream regulator of BRCA1, should also alter sensitivity to
the HR-mediated repair. Direct targeting of the predicted
miR-182-5p-binding site in CHEK2 was confirmed by dual
luciferase assay (P < 0.05) (Fig. 1D). We then used the
BRCA1 wild-type MDA-MB-231 cells transiently transfected
with miR-182-5p mimics in PARP inhibition assays, using
different concentrations of ANI (PARP1 inhibitor 4-amino-
1,8-naphthalimide) ranging from 0 to 10 µM. These cells
were also shown to have an ∼1000-fold increase in the ex-
pression of miR-182-5p relative to the negative control mim-
ic in the MDA-MB-231 cells (Fig. 5B). PARP inhibitors are
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FIGURE 3. Enrichment of targets in the DNA damage response is spe-
cific to miR-182-5p overexpression. (A) Real-time PCR analysis to eval-
uate the relative mRNA levels of known DNA repair genes was
performed in MDA-MB-231 cells transiently transfected with 20 nM
miR-182-5p mimic or negative mimic. (∗) Significant changes (P <
0.05). Data were normalized using HPRT as the internal control. The re-
sults shown are from three independent biological replicates, each per-
formed in technical quadruplicates. (B) Functional enrichment analysis
was performed using biotin-enriched targets of several miRNAs includ-
ing miR-182-5p. As shown, the canonical pathway “Role of BRCA1 in
DNA Damage Response” is highly significant in the miR-182-5p pull-
down with its −log(significance) at least four standard deviations
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the other miRNAs. This confirms that the enrichment seen for targets
in the DNA damage response is miR-182-5p specific and not occurring
by chance.
Krishnan et al.
234 RNA, Vol. 19, No. 2
 Cold Spring Harbor Laboratory Press on December 9, 2015 - Published by rnajournal.cshlp.orgDownloaded from 
cytotoxic in cells deficient in HR-mediated repair, because
the inhibitors suppress base excision repair (BER), which
would normally compensate an HR deficiency. Increased
sensitivity to PARP inhibitors would therefore indicate a re-
duction in HR function, and reintroduction of a miR-182-5p
target ORF should rescue the phenotype (Fig. 5A).
As previously reported (Moskwa et al. 2011), overexpres-
sion of miR-182-5p sensitized the cells to PARP inhibition,
as measured by clonogenic survival assays. We confirmed
that reintroduction of the BRCA1 ORF could rescue this phe-
notype (Fig. 5C) with a P-value < 0.05 at 0.01 µM and 0.1 µM
showing 10%–20% increase in rescue of the cells. Our results
also demonstrate that the phenotype can be rescued by
CHEK2, where similar results were obtained with 20%–
30% increase in survival at the 0.1 and 1 µMconcentrations of
the PARP inhibitor (P-value < 0.05), indicating that CHEK2
is another target of miR-182-5p that contributes to this
phenotype.
Validation of predicted binding sites
in MDA-MB-231 cells
Since the original target identification analysis was performed
in the nonmalignant HEK293T cell lines, we sought to vali-
date the interaction between miR-182-5p and some of the
genes enriched in the biotin pull-down using MDA-MB-
231 breast cancer cells. We selected genes for which there
was a single predicted binding site, for validation in luciferase
assays. The predicted binding sites (and ∼60 nt of surround-
ing sequence) were cloned into the 3′ UTR of the Dual
Luciferase pmiRGlo vector and transiently transfected into
cells. Luciferase activity, indicative of translation from the
plasmid, was measured in the presence of miR-182-5p mimic
or negative control mimic and normalized using Renilla ac-
tivity. Using this approach, we were able to validate seven
out of eight of the targets picked (87.5%) (Fig. 6), including
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CDKN1B. These data further strengthen our hypothesis that
miR-182-5p targets the DNA repair pathway through a net-
work of functionally related genes. Additionally, the high
rate of validation seen here contrasts favorably with valida-
tion rates based on TargetScan predictions alone (40%)
(Cloonan et al. 2008), and confirms the ability of the biotin
pull-down approach to enrich for genuine biological targets.
miR-182-5p is frequently up-regulated in human
breast cancer
Although miR-182-5p has been shown to be important for
development of breast cancer in cell lines andmice, no screens
have been performed to determine its relevance to human
breast cancer subtypes. We extended the analysis of miR-
182-5p expression to a cohort of human breast cancer patient
samples (from the Brisbane Breast Bank, The University of
QueenslandCentre forClinical Research,UQCCR). The sam-
ple cohort (n = 40) included “Invasive Ductal Carcinomas–
No Special Type” (IDC-NST) of different molecular subtypes
including triple negative (n = 18); Her2+ (n = 4), ER+/PR+ (n
= 9); Invasive Lobular Carcinomas (ILC) (n = 3); and normal
breast tissue (n = 6) (Supplemental Table 5). We included
several molecular subtypes of breast cancer and assayed the
expression levels of miR-182-5p relative to an endogenous
controlRNU6B, using qRT-PCR.As shown inFigure 7 (upper
panel), miR-182-5p is highly expressed (log10 fold-change
[tumor/normal] >1.5) in 32/40 tumor samples (∼80%) as-
sayed relative to the normal controls, and all but one sample
had higher expression in the tumors than any of the normal
controls. The average expression of miR-182-5p in every tu-
mor subtype is significantly higher (P < 0.0001) than the av-
erage expression across the normal breast tissue (Fig. 7,
upper panel). Expression of miR-182-5p is highest across
B
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the ER+/PR+ luminal subtype; however, the expression of
miR-182-5p is highly variable across the triple negative tu-
mors, perhaps indicative of the heterogeneitywithin this class.
To confirm the relevance of miR-182-5p in an indepen-
dent cohort of human breast cancers, we downloaded
miRNA-seq data from the Cancer Genome Atlas (TCGA)
data portal (https://tcga-data.nci.nih.gov/tcga/), which in-
cluded both tumor (n = 741) and normal tissues (n = 99).
The relative abundance of miRNAs was counted, and shown
in Figure 7 (lower panel) is the reads per million of miR-182-
5p across both the tumor and normal cohort, where we find a
significant difference (P < 0.0001) in its level of expression.
These results confirm that miR-182-5p is an important
miRNA relevant to human cancer and that further study is
warranted to clearly delineate its role in the pathogenesis
and progression in specific breast cancer subtypes.
DISCUSSION
In this study, we have characterized transcriptome-wide
mRNA targets of miR-182-5p using the affinity copurifica-
tion of mRNA bound to biotin-labeled miRNAs (Cloonan
et al. 2011). Gene set enrichment analysis (GSEA) of miR-
182-5p targets revealed that the DNA damage response was
a core molecular pathway regulated by this miRNA. This
pathway is critical in the normal functioning and replication
of cells, and disruption can cause cellular transformation.
PARP plays a key role in DNA repair via the base excision re-
pair (BER) pathway. When PARP is inhibited, single-strand
breaks (SSBs) degenerate to lethal DSBs, which, in the case
of BRCA-negative cells or cells deficient in HR, leads to
cell death (Bryant et al. 2005; McCabe et al. 2006).
Importantly, we were able to partially rescue miR-182-5p-
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induced sensitivity to PARP inhibitors by restoring either
BRCA1 or CHEK2 expression. Moskwa et al. (2011) previ-
ously concluded that BRCA1 was the key gene responsible
for the miR-182-5p-induced sensitivity for PARP inhibitors,
because 100% reversal of the sensitivity was observed upon
reintroduction of BRCA1. However, the overexpression of
BRCA1 under a strong promoter could easily compensate
for the relatively weaker disruption to the pathway achieved
by induction of an miRNA, and hence mask the contribution
of other pathway members. Our results directly demonstrate
that CHEK2 contributes to the miR-182-5p-induced sensi-
tivity to PARP inhibition, but also suggest that other mem-
bers of the pathway could contribute as well, confirmed by
the luciferase assay validation in the breast cancer cells (Fig.
6). Together, repression of DNA damage repair could lead
to genomic instability followed by cellular transformation
(Fig. 8).
One of the well-studied consequences of suppressing the
repair of DNA damage is the activation of apoptotic path-
ways, and this seems counterintuitive for a potential driver
of tumorigenesis. There are two hypotheses that could ex-
plain this apparent contradiction. The first is that the com-
bined effect of miR-182-5p targeting across a broad range
of genes involved in DNA damage repair would manifest as
a reduction in the fidelity of DNA repair, rather than a failure
of this pathway. This would increase the burden of mutation
in these cells, possibly quite slowly, allowing the cells to ac-
commodate and adapt to a modestly increasing mutation
load. Such a hypothesis, while plausible, has not been directly
tested in this study. The second (but not mutually exclusive)
hypothesis is that miR-182-5p also directly suppresses the
apoptotic pathway triggered by DNA damage. CDKN1B
(p27KIP1) was a target of miR-182-5p identified by the biotin
pull-down and validated using luciferase assay. This gene reg-
ulates G0-to-S phase transitions by interacting with cyclin-
dependent kinases (CDKs) (Hengst and Reed 1998; Sherr
and Roberts 1999), and overexpression of this gene has
been shown to trigger apoptosis in the MDA-MB-231 cell
line (Katayose et al. 1997) with pro-apoptotic properties in
other cancers (Fujieda et al. 1999; Wu et al. 1999; Tenjo
et al. 2000). Apoptosis has recently been identified as one
of the deregulated pathways by the miR-182-5p cluster in
medulloblastoma (Weeraratne et al. 2012), and suppression
of CDKN1B by miR-182-5p, along with other pro-apoptotic
genes like BAK and BAX (Supplemental Table 1), suggests
that apoptosis triggered by DNA damage could be deregulat-
ed by this miRNA.
Not all targets of miR-182-5p easily fit into the model pro-
posed here (Fig. 8). Some targets—like BTRC, SKP1, SKP2,
and the components of the SCF complex—are suppressors
of DNA damage repair, andmiR-182-5p suppression of these
proteins would act to ensure genome fidelity. Relevant to this
point are the conflicting reports regarding miR-182-5p’s mo-
lecular role in tumorigenesis. Whereas there appears to be an
oncogenic role for this miRNA in some cancers including
melanoma (Segura et al. 2009), endometrioid endometrial
cancer (Myatt et al. 2010), and glioma (Jiang et al. 2010);
in others, such as lung adenocarcinoma (Sun et al. 2010;
Zhang et al. 2011) and human gastric adenocarcinoma
(Kong et al. 2012), its role is more akin to that of a tumor sup-
pressor. Such dual-function miRNAs have been previously
reported: miR-26a (Sander et al. 2008; Huse et al. 2009;
Kota et al. 2009; Kim et al. 2010), miR-205 (Iorio et al.
2007, 2009; Gandellini et al. 2009; Wu et al. 2009), and
miR-17-5p (Hossain et al. 2006; Mraz et al. 2009; Yu et al.
2010; Li et al. 2011) are all characterized examples. In the
latter case, the molecular mechanism underlying the dual
phenotype was uncovered through systematic screening of
predicted targets through luciferase assays (Cloonan et al.
2008). Targeting both inhibitors and activators of DNA dam-
age repair could either promote or inhibit genomic stability
depending on the relative expression levels of those targets
—and this could explain the conflicting reports of miR-
182-5p’s role in tumorigenesis. For a firm conclusion to be
made, independent validation of each target would be re-
quired. While the biotin pull-down has been optimized for
high specificity, the presence of false-positive targets in the
enrichment analysis should be considered while interpreting
these results. Ongoing work suggests that the rate of false pos-
itives is ≤5% (data not shown), which would not be high
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enough to interfere with GSEA but may become critical when
considering individual targets.
Many of the key genes involved in DNA repair also have
annotated roles in the cell cycle, and GSEA correctly identi-
fied the cell cycle as an important molecular function of
miR-182-5p targets. Although we found that ectopic expres-
sion of miR-182-5p was not sufficient to drive proliferation
(confirming earlier reports) (Moskwa et al. 2011), we did
observe minor cell cycle effects consistent with a DNA dam-
age response. The HR-mediated repair is restricted to the
S and G2 phases of the cell cycle (Moynahan et al. 1999;
Moynahan and Jasin 2010) by several factors and detection
of double-strand breaks would typically result in a G2 arrest.
In our analysis with overexpression of miR-182-5p in HeLa
cells (which would suppress this checkpoint), we see fewer
cells in both the S and G2 phases with increased accumulation
in the G1 phase. This could be a result of a disrupted G2 arrest
as a result of the deregulated HR-mediated repair pathway
(Fig. 8). Other studies have shown the miR-182-5p in con-
junction with miR-96 and miR-27a (Guttilla and White
2009) can alter proliferation rates in MCF-7 breast cancer
cells; hence, it could be that concomitant targeting of genes
by all members of the miR-182-5p cluster and other mature
miRNAs is essential to drive this phenotype.
We confirm the relevance of miR-182-5p dysregulation to
human breast cancer by showing that this miRNA is overex-
pressed across a panel of human breast cancer samples, which
belong to several molecular and pathological subtypes. Al-
though overexpressed in the triple negative subtype, the var-
iability of miR-182-5p expression within this subtype was
substantially more than seen in any other classification. Tri-
ple negative tumors are typically characterized by BRCA defi-
ciency and a disrupted HR pathway. Given miR-182-5p’s role
in HR-mediated DNA repair, it is possible that transcription
factors that typically dysregulate protein components of this
pathway are also dysregulating miR-182-5p transcription. In
melanoma, miR-182-5p has been associated with the inva-
sion/metastatic signaling cascade (Segura et al. 2009). We
did not find a strong association betweenmiR-182-5p and the
metastatic lymph node status of samples, suggesting that its
role in breast cancer is more likely tumorigenesis than tumor
progression. However, further studies using matched prima-
ry and distant metastatic samples followed by functional val-
idations are required to elucidate miR-182-5p’s molecular
role in each cancer subtype.
Of particular relevance to therapeutic biomarkers is miR-
182-5p’s ability to induce sensitivity to PARP inhibitors
through multiple effectors. This result could be of immense
therapeutic value, potentially widening the opportunity to
expand treatment from breast cancers with mutations in
BRCA1/2 to tumors with miR-182-5p disrupted HR-mediat-
ed pathways. It is currently not clear what percentage of the
sporadic breast tumor patients with a functional HR pathway
would respond to treatment with PARP inhibitors. We have
now shown miR-182-5p as a potential regulator of the HR-
mediated DNA repair pathway, which is the major determi-
nant of a cell’s sensitivity to PARP inhibition. Further studies
are required to address if the status of BRCA mutation and
overexpression of miR-182-5p are mutually exclusive and if
either one is sufficient to make cells PARP-inhibition sensi-
tive. This could include nonbreast cancer tumors, such as
ovarian cancer, where several sporadic cancer types display
a “BRCA-like” phenotype (Turner et al. 2004). Intriguingly,
overexpression of miR-182-5p has recently been shown to
target BRCA1 in ovarian papillary serous carcinoma (Liu
et al. 2012). An important subject of future studies would
be to determine how well miR-182-5p performs as a prog-
nostic or therapeutic biomarker.
MATERIALS AND METHODS
Cell culture
HEK293T, MDA-MB-231, and HeLa cells were maintained in
DMEM (Life Technologies) with 10% FBS and 1% Penicillin–
Streptomycin (Life Technologies) and grown in a 5% CO2 atmo-
sphere at 37°C. MDA-MB-231 and HeLa cell lines were purchased
from Cell Bank; the HEK293T cell line was purchased from ATCC.
Biotin pull-downs, microarray hybridizations,
and analysis
Pull-downs of miR-182-5p targets were carried out as previously de-
scribed (Cloonan et al. 2011), using biotin-labeled oligonucleotides
specific for miR-182-5p (Supplemental Table 6). Briefly, 50 pmol of
biotin-labeled oligos (IDT) was transiently transfected into
HEK293T cells and cultured for 24 h. This was followed by cell lysis
and binding of 50 µL (Streptavidin), myOne C1 Dynabeads
(Invitrogen) to the RNA fraction for enrichment. Fifty nanograms
of captured mRNA fractions (three independent biological repli-
cates) was amplified and labeled using the Illumina Total Prep
RNA amplification kit (Ambion) as per the manufacturer’s instruc-
tions. Samples were profiled on Illumina HumanHT-12 chips along
with control RNA from mock-transfected cells.
Microarray data were normalized using the lumi package (Du
et al. 2008) by applying background adjustment, variance-stabilizing
transformation (Lin et al. 2008), and robust spline normalization
(Workman et al. 2002) successively. The lmFit and eBayes functions
in the limma package (Smyth 2004) were used to test differential ex-
pression between the pull-down samples and the controls (Cloonan
et al. 2011). The false discovery rate (FDR) was calculated to account
for multiple testing (Benjamini and Hochberg 1995). Probes that
met the 5% FDR threshold (for one-sided tests) were considered sig-
nificantly enriched in the pull-down. The transcripts (ENSEMBL
V62) to which theymatched exactly were considered putative targets
of that miRNA. The targets enriched using the biotin pull-downs
were analyzed using Ingenuity Pathway Analysis as previously de-
scribed (Cloonan et al. 2008).
Stable cell line generation
MDA-MB-231 cells stably expressing miR-182-5p were generated
using the Mir-X Inducible miRNA Systems (Clontech). Briefly,
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MDA-MB-231 cells were transfected with the pTet-on Advanced
Vector using Lipofectamine 2000 (Life Technologies Australia, Invi-
trogen Division), and cells stably expressing the plasmid were select-
ed using 800 µg/mL G418 (Life Technologies); maintenance
concentration: 400 µg/mL G418. Primers (Supplemental Table 6)
were used to amplify the miR-182-5p hairpin from human genomic
DNA and cloned into the pmRI-ZsGreen I vector plasmid
supplied and subsequently transfected into the 231-pTet-on parent
line. Cells stably expressing pmRi-Zsgreen-miR-182-5p were select-
ed using 1 µg/mL puromycin and further maintained in 0.5 µg/mL
puromycin. Stable expression of miR-182-5p was confirmed using
the miRNA Taqman Assay (Applied Biosystems) specific for miR-
182-5p (Fig. 2A).
Clonogenic cell survival assay
MDA-MB-231 cells were seeded overnight (2 × 105 cells/well in a
12-well plate) and transfected with 10 nM miRNA mimics
(Ambion). In rescue experiments, miR-182-5p or control mimics
were cotransfected with 0.5 µg of BRCA1 or CHEK2 cDNA clones.
After 48 h, 500 cells in 2 mL of DMEM media (10% FBS, v/v)
were seeded on six-well plates in triplicate and incubated overnight
before treatment. PARP inhibitors (4-amino-1, 8-naphthalimide
[Sigma-Aldrich] in DMSO) were added to the growth media at 0
µM, 0.01 µM, 0.1 µM, 1 µM, and 10 µM concentrations. Cells in
the presence of PARP inhibitor were allowed to form colonies for
14 d. For evaluation, formed colonies were stained with Crystal Vio-
let and surviving colonies containing more than 50 cells were count-
ed. The plating efficiency was 20%–35%.
Flow cytometry for cell cycle analysis
HeLa cells were transiently transfected using 50 nM miR-182-5p
mirVana mimic (Life Technologies) using Lipofectamine 2000
(Invitrogen) as per the manufacturer’s instructions. All cells were
harvested and fixed in 70% ethanol overnight at −20°C. DNA was
stained using 10 μg/mL propidium iodide (Sigma-Aldrich), and
RNA was removed using 200 μg/mL RNase A (Sigma-Aldrich).
Cells were filtered through a 35-μm cell strainer mesh
(BectonDickinson) and analyzed on Becton Dickinson LSR II flow
cytometer fitted with a 488-nm laser. Cell data were gated and ana-
lyzed using FlowJo 7.2.2 (Tree Star, Inc.). The same fixing and
FACS protocol was applied to MDA-MB-231 cells stably overex-
pressing miR-182-5p.
Dual luciferase assay to validate predicted binding sites
Predicted target sites of miR-182-5p were cloned into the Nhe1 and
SalI sites of pmirGLO Dual-Luciferase miRNA Target Expression
Vector (Promega). Synthetic oligos (Supplemental Table 6) corre-
sponding to 60 nucleotides surrounding the target sequence were
annealed before ligation into the pmirGlo plasmid. All constructs
were verified by sequencing. HEK293T or MDA-MB-231 cells
were cotransfected with 50 ng of a pmirGlo construct and miR-
182-5p or negative mimic (Ambion) to a final concentration of
20 nM. Post-transfection, cells were incubated for 48 h prior to as-
saying. Luciferase activity was assayed using the Dual Luciferase
Reporter Assay System (Promega) and detected on a Wallac 1420
luminometer (PerkinElmer). Luciferase activity was normalized to
the internal control, Renilla activity in each well. Assays were con-
ducted in triplicate and independently repeated three times.
MTT proliferation assays
Stable pmRi-MDA-MB-231 cell lines overexpressing miR-182-5p
(1000 ng/mL doxycycline) and parent stables (with no doxycycline)
were plated at 1 × 104 cells per well. MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide) activity was assayed using
a Cell Growth Determination Kit (Sigma-Aldrich) according to the
manufacturer’s instructions and detected on a PowerWave XS spec-
trophotometer (BioTek).
Clinical samples, RNA purification, and qRT-PCR
analyses
Human breast tumors were derived from the Brisbane Breast Bank,
collected from consenting patients and with ethical approval from
the research ethics committees of the Royal Brisbane & Women’s
Hospital and the University of Queensland. Histological type, tumor
grade, tumor size, lymph node status, and ER, PR, and HER2 status
were obtained from the pathology reports. ER, PR, and HER2 bio-
markers were used to infer molecular subtype as luminal, HER2, or
triple negative. Total RNA from human tumor samples was extract-
ed using tumor homogenization followed by TRIzol extraction
(Invitrogen).
Total RNA was purified from cell lines using the miRNeasy Mini
Kit (QIAGEN), and RNA integrity was assessed using an Agilent
Bioanalyzer 2100. For mature miRNA, cDNA (5–10 ng of total
RNA) was synthesized using a Taqman MicroRNA RT Kit
(Applied Biosystems), and qRT-PCR was performed using a miR-
182-5p MicroRNA Taqman assay (Applied Biosystems). For
mRNA expression analysis, 500 ng of total RNA was reverse-tran-
scribed using SuperScript III (Invitrogen), and a 1:50 dilution of
the cDNA was used in the real-time PCR reaction. All RT-PCR
was performed on an Applied Biosystems 7000 Sequence
Detection System. For small RNA expression analysis, RNU6B was
used as an endogenous control to normalize the data.
DATA DEPOSITION
The raw microarray data used in this study are available from
the Gene Expression Omnibus (GEO) under accession number
GSE38593.
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